Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of EMB-001 in Smokers
NCT02406066Phase 1Completed
- Sponsor
- Embera NeuroTherapeutics
- Start
- Mar 2015
- Primary completion
- Dec 2015
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of metyrapone and oxazepam in Tobacco Use Disorder (TUD) (4 arms), sponsored by Embera NeuroTherapeutics. Primary endpoint: Safety and Tolerability at Day 17. Started Mar 2015; status: completed.
02
Drugs
metyraponeoxazepam
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT02406066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406066.